Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 14612890

A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Br J Cancer
Publication date
2003 Nov 17
First author
Vasey PA

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Vasey PA
      type
      Author
    2. name
      McMahon L
      type
      Author
    3. name
      Paul J
      type
      Author
    4. name
      Reed N
      type
      Author
    5. name
      Kaye SB
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Vasey PA
      type
      Author
    2. name
      McMahon L
      type
      Author
    3. name
      Paul J
      type
      Author
    4. name
      Reed N
      type
      Author
    5. name
      Kaye SB
      type
      Author
    bibliography ids
    1. nci-bib-2e48ca3d3cb0cc250c3609d1
    book metadata
    content sha256
    1c298daa22ffb7e666b60621b2a85acf04f659dc434ed5ba9d552c77ff4f6c8a
    document type
    citation
    dois
    1. 10.1038/sj.bjc.6601381
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:14612890
    immutable id
    pubmed:14612890@1c298daa22ffb7e666b60621b2a85acf04f659dc434ed5ba9d552c77ff4f6c8a
    journal
    abbreviation
    Br J Cancer
    issn electronic
    1532-1827
    issn print
    0007-0920
    issue
    10
    name
    British journal of cancer
    nlm unique id
    0370635
    pages
    1843-8
    volume
    89
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      14612890
      provenance
      batch id
      aee154f17d1b0501fe1f
      provider
      NCBI PubMed ESummary
      record sha256
      bae14f2455135ff9c89464621f562f2ce1cc5e48f30467a34698de57f8d79140
      response sha256
      75a826407a9022d376294c7400982e19a458458cea55b2628fd3fddd75bc0f08
      retrieved at
      2026-09-09T23:45:53.270896+00:00
      publication date
      display
      2003 Nov 17
      precision
      day
      year
      2003
      publication types
      1. Clinical Trial
      2. Clinical Trial, Phase II
      3. Journal Article
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/14612890/
      title
      A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer.

      Preserved source evidence · Not medical advice